Input Stories

Manufacturer Bolsters U.S. Pharma Supply Chain

By NAM NewsroomSeptember 10, 2026

Virginia-based drug maker Phlow Corp. is aiming to boost the domestic supply chain of ingredients for critical biopharmaceuticals (PR Newswire).

What’s going on: The Alliance for Building Better Medicine, a group co-founded by Phlow, will receive a $15.97 million investment from the U.S. Economic Development Administration to establish a wholly domestic route for pharmaceutical commercialization in Virginia, it announced in late July.

  • Led by nonprofit drug manufacturer Civica and supported by Phlow and chemical supply chain design firm Occam Systems, the project “will focus on four essential sterile injectable medicines used every day in emergency, anesthesia and critical care settings: ketamine, midazolam, norepinephrine and succinylcholine,” and the finished medications will be produced at a Virginia plant.

Why it’s important: “Today, more than 130 million Americans rely on medicines produced through increasingly complex global manufacturing networks. … [P]ersistent shortages continue to affect many critical therapies …,” the Alliance pointed out in its press release on the Virginia project.

  • “The end-to-end commercialization project is designed to strengthen America’s ability to develop, commercialize and manufacture medicines domestically while expanding U.S. capacity for both established and innovative therapies.”

Teamwork makes the dream work: The EDA funding will help the initiative realize long-sought health goals, said Alliance Chairman and Phlow Chief of Staff Robby Demeria (MedPath).

  • “This milestone reflects what becomes possible when organizations commit to solving challenges that no single company can solve alone. From the beginning, the Alliance has been built on the belief that lasting progress comes through collaboration.”

All in on American manufacturing: Early this year, Phlow and injectable drugs and delivery systems company Fresenius Kabi announced a partnership to onshore production of the active pharmaceutical ingredient in epinephrine injections, which have faced shortages in the U.S. (Fierce Pharma).

  • Also this year, Phlow began a collaboration with biotechnology company Enveda to use artificial intelligence in API manufacturing process development (Contract Pharma).